Last checked at 22 Nov 2022 07:00
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or 'the Group')
Distribution agreement for OrthoPure® XT in Germany
Second European distribution agreement signed in 2022 as part of the European growth strategy
Tissue Regenix Group (AIM: TRX), the regenerative medical devices company, announces that it has signed an exclusive distribution agreement with 2med GmbH ('2med'), a Hamburg-based service provider for surgical and orthobiological treatments of the musculoskeletal system, for the distribution of OrthoPure® XT in Germany.
The multiyear distribution agreement currently covers Germany. However, it also has the potential for extension into additional territories covered by 2med representatives. 2med is an independent specialist dealer of surgical and biological therapy procedures for shoulder, knee, foot and ankle, with a focus on treatments that support an active and independent lifestyle.
The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's patented dCell® technology and is the only available non-human biologic graft indicated for certain ligament reconstruction procedures. The CE-marked OrthoPure® XT can be used for revision of anterior cruciate ligament (ACL) reconstruction procedures and reconstruction of other knee ligaments, including multi-ligament and primary procedures when the autograft is not an option.
Thomas Guenther, Commercial Director at 2med, commented: "2med are delighted to be representing OrthoPure® XT in Germany. The initial feedback from our knee surgeons is very positive and we are excited to offer this new, easy to use option for German patients with damaged ACL and other knee ligaments."
Daniel Lee, Chief Executive Officer of Tissue Regenix Group, commented: "Following the success of our partnership with Geistlich Biomaterials Italia, that we announced in March 2022, we are pleased to have signed this distribution agreement with 2med for Germany. 2med's work with doctors and patients, to offer advanced treatments and minimise rehabilitation times, are aligned with this innovative product and has made 2med one of the leading specialist dealers in Germany. We look forward to working with 2med and continuing to expand the use of OrthoPure® XT across Europe."
For more information:
Tissue Regenix Group plc | www.tissueregenix.com | |
David Cocke, Chief Financial Officer | Via Walbrook PR | |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) | Tel: +44(0)20 7710 7600 | |
Ben Maddison / Nick Harland / Kate Hanshaw | ||
Walbrook PR Ltd | Tel: +44(0)20 7933 8780 | |
Alice Woodings / Lianne Applegarth | TissueRegenix@walbrookpr.com | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.